Relay Therapeutics Inc (RLAY) Stock Price, Quote & News

Company Profile

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 370 8837

Website: www.relaytx.com

Address:

399 Binney Street, 2nd Floor, Cambridge, United States

JarvisFlow Aug. 26 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Relay Therapeutics ( $RLAY ), setting the rating to Buy with a target price of 16 → 14.

1 · Reply

TalkMarkets Aug. 25 at 7:15 PM

#AI-Focused Drug Discovery Stock RXRX Was Down 14% Last Week - Here's Why $RXRX Also $JNJ $ABCL $RLAY $ABSI https://talkmarkets.com/content/stocks--equities/ai-focused-drug-discovery-stock-rxrx-was-down-14-last-week-heres-why?post=517866

0 · Reply

Breck100 Aug. 19 at 5:31 PM

$RLAY 8/12/25 Leerink Partners analyst Andrew Berens reiterated a Buy rating on Relay Therapeutics today and set a price target of $12.00.

0 · Reply

Breck100 Aug. 8 at 4:57 PM

$RLAY 8/8/25

1 · Reply

JarvisFlow Aug. 8 at 4:14 PM

Raymond James updates rating for Relay Therapeutics ( $RLAY ) to Strong Buy, target set at 29 → 19.

0 · Reply

birddog_ Aug. 8 at 1:32 PM

$RLAY Given the combination of clinical validation, financial conservatism, and trial momentum, there’s clear potential for meaningful price appreciation… especially if Phase 3 enrollment proceeds smoothly and interim readouts emerge positively. Based on existing data from phase 1/2, this is more likely than not! Bottom Line: Relay is making smart strides - financially solid, clinically validated, and operationally disciplined. It’s positioning itself well for long-term upside!!

0 · Reply

Thestocktraderhubzee Aug. 8 at 10:08 AM

WATCHLIST AUG 08 2025 $RLAY RLAY stock has given up its prior gain. Relay Therapeutics shares were trading higher after the company reported better-than-expected Q2 financial results. $UMC UMC Becomes First Semiconductor Foundry Worldwide To Receive SBTi Validation For 1.5°C-Aligned Net-Zero Targets $BA Boeing And Spirit AeroSystems Merger Gets Green Light From UK's Competition And Markets Authority With No Phase 2 Review $BNTX Curevac And GSK Have Agreed To Resolve And Dismiss All Pending Patent Litigation In The US With BioNTech And Pfizer, Related To mRNA-Based COVID-19 Vaccines, CureVac and GSK Will Receive $740M And Single-Digit Royalties $LASR Needham Maintains Buy on nLight, Raises Price Target to $28

0 · Reply

Cajo0404 Aug. 7 at 8:14 PM

$RLAY Beat on ER Still in its infancy. Wait till they find it!

0 · Reply

Breck100 Aug. 7 at 7:09 PM

$RLAY Need good ER here

0 · Reply

birddog_ Aug. 6 at 5:59 PM

$RLAY not sure why retail has not uncovered this one … interested in hearing tomorrow’s after hours earnings/update call. Very bullish.

1 · Reply

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Aug 2, 2025, 8:03 AM EDT - 24 days ago

Relay Therapeutics: What's Next For H2 2025?

Jul 31, 2025, 4:05 PM EDT - 26 days ago

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

Jun 11, 2025, 4:05 PM EDT - 2 months ago

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

Jun 2, 2025, 7:00 AM EDT - 3 months ago

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

May 29, 2025, 4:05 PM EDT - 3 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 8, 2025, 4:05 PM EDT - 3 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

May 5, 2025, 4:05 PM EDT - 4 months ago

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Apr 28, 2025, 4:05 PM EDT - 4 months ago

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

Apr 12, 2025, 9:28 AM EDT - 4 months ago

Relay Therapeutics: Trying To Find That Right Price

Feb 26, 2025, 4:05 PM EST - 6 months ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 19, 2025, 4:05 PM EST - 6 months ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Feb 14, 2025, 2:17 AM EST - 6 months ago

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Jan 7, 2025, 4:05 PM EST - 8 months ago

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:00 AM EST - 9 months ago

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Dec 9, 2024, 4:05 PM EST - 9 months ago

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Dec 3, 2024, 8:01 AM EST - 9 months ago

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Dec 3, 2024, 8:00 AM EST - 9 months ago

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Nov 6, 2024, 4:05 PM EST - 10 months ago

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 30, 2024, 4:05 PM EDT - 10 months ago

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Sep 16, 2024, 4:57 PM EDT - 1 year ago

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Sep 11, 2024, 8:15 AM EDT - 1 year ago

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11, 2024, 8:06 AM EDT - 1 year ago

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GME WOOF

Sep 10, 2024, 8:21 PM EDT - 1 year ago

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Sep 10, 2024, 2:50 PM EDT - 1 year ago

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market

Sep 10, 2024, 10:03 AM EDT - 1 year ago

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

JCI DK EQR ORCL

Sep 9, 2024, 4:34 PM EDT - 1 year ago

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Sep 9, 2024, 2:16 PM EDT - 1 year ago

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher

Sep 9, 2024, 11:30 AM EDT - 1 year ago

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Sep 9, 2024, 7:04 AM EDT - 1 year ago

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Sep 9, 2024, 6:55 AM EDT - 1 year ago

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

May 21, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2024, 8:30 AM EDT - 1 year ago

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Feb 26, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Feb 22, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Feb 15, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

Feb 1, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 7:00 AM EST - 1 year ago

Relay Therapeutics Announces $30 Million Private Placement Financing

Jan 2, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 7, 2023, 4:05 PM EST - 1 year ago

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference

Nov 6, 2023, 2:05 AM EST - 1 year ago

Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Sep 18, 2023, 4:05 PM EDT - 2 years ago

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

JarvisFlow Aug. 26 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Relay Therapeutics ( $RLAY ), setting the rating to Buy with a target price of 16 → 14.

1 · Reply

TalkMarkets Aug. 25 at 7:15 PM

0 · Reply

Breck100 Aug. 19 at 5:31 PM

$RLAY 8/12/25 Leerink Partners analyst Andrew Berens reiterated a Buy rating on Relay Therapeutics today and set a price target of $12.00.

0 · Reply

Breck100 Aug. 8 at 4:57 PM

$RLAY 8/8/25

1 · Reply

JarvisFlow Aug. 8 at 4:14 PM

Raymond James updates rating for Relay Therapeutics ( $RLAY ) to Strong Buy, target set at 29 → 19.

0 · Reply

birddog_ Aug. 8 at 1:32 PM

0 · Reply

Thestocktraderhubzee Aug. 8 at 10:08 AM

0 · Reply

Cajo0404 Aug. 7 at 8:14 PM

$RLAY Beat on ER Still in its infancy. Wait till they find it!

0 · Reply

Breck100 Aug. 7 at 7:09 PM

$RLAY Need good ER here

0 · Reply

birddog_ Aug. 6 at 5:59 PM

$RLAY not sure why retail has not uncovered this one … interested in hearing tomorrow’s after hours earnings/update call. Very bullish.

1 · Reply

fredbull Jul. 28 at 2:50 PM

$RLAY $7-10 today. Hidden. So far

0 · Reply

ZacksResearch Jul. 25 at 3:34 PM

$RXRX vs. $RLAY: Why RXRX is the Better Bargain in AI-Driven Drug Discovery 🎯 Recursion Pharmaceuticals boasts a diverse pipeline and strategic collaborations, like with NVIDIA, aiming to revolutionize drug discovery with AI. In contrast, Relay Therapeutics relies heavily on its lead candidate, RLY-2608, for two indications, limiting its growth prospects. Discover why RXRX offers better growth potential despite higher valuation, with a strong cash balance supporting its operations into mid-2027 👉 https://www.zacks.com/stock/news/2618085/rxrx-vs-rlay-which-precision-biotech-stock-is-a-better-bet-now?cid=sm-stocktwits-2-2618085-body-3951&ADID=SYND_STOCKTWITS_TWEET_2_2618085_BODY_3951

0 · Reply

TalkMarkets Jul. 23 at 9:46 PM

3 Of The 5 Stocks In Our AI-Focused Drug Discovery Portfolio Were Up Significantly Last Week - Here's Why $SDGR $ABCL $RLAY $ABSI $RXRX https://talkmarkets.com/content/stocks--equities/3-of-the-5-stocks-in-our-ai-focused-drug-discovery-portfolio-were-up-significantly-last-week-heres-why?post=511045

0 · Reply

TheDrunkTrader69 Jul. 23 at 3:30 PM

$RLAY

0 · Reply

theBigDollarski Jul. 23 at 3:27 PM

$RLAY bought my last bunch before liftoff. See you all above 10

0 · Reply

MajorStockTradingLLC Jul. 17 at 2:42 PM

$RLAY Took a micro position in this as "Pauli Two Shoes" my Ai bot said this was a buy.

0 · Reply

Baseball89 Jul. 17 at 2:32 PM

$RLAY $IMRN

0 · Reply

RunnerSignals Jul. 9 at 8:26 PM

$GNS $LXRX $COGT $FUTU $RLAY opened red, closed green with strength. market warriors in action today

0 · Reply

ZacksResearch Jul. 7 at 3:23 PM

$RXRX down 22% YTD — Can it turn the tide? After shelving three drug candidates, RXRX focuses on promising REC-4881, showing a 43% reduction in polyp burden in early trials. More data expected in H2 2025, but competitive pressure from $RLAY and $SDGR, who also use AI-driven platforms, looms. Explore RXRX’s potential turnaround here 👉 https://www.zacks.com/commentary/2565928/will-rxrxs-shift-in-pipeline-focus-help-restore-investor-faith?cid=sm-stocktwits-2-2565928-body-850&ADID=SYND_STOCKTWITS_TWEET_2_2565928_BODY_850

0 · Reply

ZacksResearch Jul. 2 at 3:53 PM

$RXRX dips 24.1% YTD — facing competitive pressures in the TechBio space Despite its innovative RecursionOS platform and partnerships with Bayer and Roche, RXRX is underperforming the industry, sector, and S&P 500. Competitive pressure from $RLAY and $SDGR adds to the challenge. Discover the full story here 👉 https://www.zacks.com/commentary/2560564/can-rxrxs-ai-based-approach-revolutionize-the-drug-discovery-process?cid=sm-stocktwits-2-2560564-body-656&ADID=SYND_STOCKTWITS_TWEET_2_2560564_BODY_656

0 · Reply

TheDrunkTrader69 Jul. 2 at 3:02 PM

$RLAY She waking up? I knew eventual she would long term holding know what you have. Very nice

0 · Reply

BBQQ Jun. 30 at 10:44 PM

$RLAY sleeper Google took a position

0 · Reply

Market Cap	636.20M
Revenue (ttm)	10.01M
Net Income (ttm)	-337.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,373.73%
Debt to Equity Ratio	0.00

Volume	441,986
Avg Vol	2,104,798
Day's Range	N/A - N/A
Shares Out	172.41M
Stochastic %K	49%
Beta	1.62
Analysts	Strong Sell
Price Target	$14.00